FIREFLY NEUROSCIENCE, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that FIREFLY NEUROSCIENCE, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.14M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $108.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $498.0K | Apr 3, 2025 |
| FY2022 | Dec 31, 2022 | $12.02M | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $15.03M | Apr 17, 2023 |
| FY2018 | Dec 31, 2018 | $8.93M | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $10.64M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $6.73M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $6.21M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $5.78M | Mar 29, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $645.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $108.0K | Mar 31, 2026 |
| FY2023 | Dec 31, 2023 | $2.61M | Mar 20, 2024 |
| FY2023 | Dec 31, 2022 | $2.86M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $3.62M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.21M | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $1.40M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.14M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $2.42M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.82M | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($19.88M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($10.46M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($2.60M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | ($17.75M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($1.13M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $413.4K | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | ($717.2K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($51.0K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $246.5K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($553.7K) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.86M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($10.05M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($3.08M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | ($5.42M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($2.63M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $411.8K | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | ($727.8K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($62.3K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $237.8K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($563.5K) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.48M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.95M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $741.0K | Apr 3, 2025 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $5.84M | Mar 20, 2024 |
| FY2023 | Dec 31, 2022 | $8.28M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $6.24M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.80M | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $1.88M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.75M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.67M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.88M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $1.75M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $1.69M | Mar 29, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.19M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($6.16M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($2.17M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | ($6.01M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($735.0K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $423.3K | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | ($917.1K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($763.5K) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $836.1K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($256.5K) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Mar 20, 2024 |
| FY2023 | Dec 31, 2022 | $535.9K | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $69.8K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $64.5K | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $8.4K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $5.8K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $840 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $13.4K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $18.2K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $32.2K | Mar 29, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.48M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.60M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.64M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $7.98M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $23.36M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $3.77M | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $2.37M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $3.02M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $3.73M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.75M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.84M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.98M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.53M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $4.25M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $5.92M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.16M | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $1.21M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.15M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.84M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.12M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.64M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($375.0K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $109.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($2.23M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2021 | $17.44M | Mar 20, 2024 |
| FY2022 | Dec 31, 2020 | $1.61M | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | $1.16M | Apr 12, 2022 |
| FY2020 | Dec 31, 2018 | $1.87M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $1.89M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $1.63M | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.18M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 31, 2026 |
| FY2023 | Dec 31, 2023 | $1.13M | Mar 20, 2024 |
| FY2023 | Dec 31, 2022 | $1.13M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $7.59M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 12, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($111.62M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($87.08M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($76.62M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | ($31.19M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($13.44M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($12.31M) | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | ($12.72M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($12.00M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($11.95M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($12.20M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $682.0K | Mar 20, 2024 |
| FY2023 | Dec 31, 2022 | $731.1K | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $4.93M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.86M | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $1.04M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.96M | Mar 30, 2020 |
| FY2019 | Dec 31, 2017 | $2.73M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $1.90M | Apr 1, 2019 |
| FY2017 | Dec 31, 2015 | $2.17M | Apr 2, 2018 |
| FY2016 | Dec 31, 2014 | $2.45M | Mar 31, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $450.0K | Mar 31, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | (10) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2018 | Dec 31, 2018 | 0 | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | 0 | Apr 12, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2018 | Dec 31, 2018 | 0 | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Mar 20, 2015 |
| FY2013 | Dec 31, 2012 | 0 | Mar 31, 2014 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13.96M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 8.12M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 3.68M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | 1.92M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 17.24M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 11.26M | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | 11.21M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 11.20M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 11.20M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 11.20M | Apr 2, 2018 |